BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)
CUSIP: 09075P105
Q4 2018 13F Holders as of 31 Dec 2018
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 26,011,000
- Total 13F shares
- 2,420,717
- Share change
- -830,223
- Total reported value
- $9,354,000
- Price per share
- $3.85
- Number of holders
- 11
- Value change
- -$3,409,943
- Number of buys
- 4
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09075P105:
Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
5.1%
|
1,318,342
|
$10,098,000 | — | 30 Sep 2018 | |
| Artemis Investment Management LLP |
13F
|
Company |
4.8%
|
1,254,853
|
$9,700,000 | — | 30 Sep 2018 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
1.1%
|
298,400
|
$2,286,000 | — | 30 Sep 2018 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.1%
|
296,233
|
$2,269,000 | — | 30 Sep 2018 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.07%
|
19,062
|
$146,000 | — | 30 Sep 2018 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.07%
|
18,500
|
$142,000 | — | 30 Sep 2018 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.06%
|
15,587
|
$120,000 | — | 30 Sep 2018 | |
| Creative Planning |
13F
|
Company |
0.05%
|
13,350
|
$102,000 | — | 30 Sep 2018 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
5,222
|
$41,000 | — | 30 Sep 2018 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
3,906
|
$30,000 | — | 30 Sep 2018 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.01%
|
3,100
|
$24,000 | — | 30 Sep 2018 | |
| C M BIDWELL & ASSOCIATES LTD |
13F
|
Company |
0.01%
|
2,500
|
$19,000 | — | 30 Sep 2018 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0%
|
1,200
|
$9,000 | — | 30 Sep 2018 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0%
|
736
|
$6,000 | — | 30 Sep 2018 | |
| Point72 Hong Kong Ltd |
13F
|
Company |
0%
|
448
|
$3,000 | — | 30 Sep 2018 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
323
|
$2,000 | — | 30 Sep 2018 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
300
|
$2,000 | — | 30 Sep 2018 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
194
|
$1,000 | — | 30 Sep 2018 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q4 2018
As of 31 Dec 2018,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,420,717 shares.
The largest 10 holders included
Artemis Investment Management LLP, FMR LLC, CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM, Vanguard Group Inc, BlackRock Inc., UBS Group AG, DEUTSCHE BANK AG\, MORGAN STANLEY, BANK OF MONTREAL /CAN/, and Tower Research Capital LLC (TRC).
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2018 vs Q3 2018 Across Filers
Q3 2018 holders
17
Q4 2018 holders
11
Holder diff
-6
| Investor | Q3 2018 Shares | Q4 2018 Shares | Share Diff | Share Chg % | Q3 2018 Value $ | Q4 2018 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.